Search

A study conducted by researchers at Kasetsart University in Bangkok, Thailand, explores the use of carbon dioxide (CO2) laser technology to modify the gas permeability of polybutylene succinate (PBS) film for food packaging. By creating holes in the film, the researchers found that they could regulate gas transmission rates, which has the potential to improve the quality and safety of food. The study specifically focused on the packaging of bananas and found that microperforated PBS films with a certain number of holes and a specific pulse length were effective in preserving banana quality. This research has been peer-reviewed and provides valuable insights into modified atmosphere packaging. [Extracted from the article]

A recent study conducted in Yamanashi, Japan, explored the effects of consuming barley b-glucan on gut microbiota and metabolome profiles. The researchers found that barley b-glucan intake increased the levels of Bacteroides, Parasutterella, and succinate in mice, which in turn improved glucose tolerance. However, this effect was attenuated in mice lacking the slc13a2 gene, which is involved in the cellular uptake of succinate. These findings suggest that barley b-glucan consumption can positively impact glucose metabolism by increasing succinate and succinate-producing bacteria in the intestines. [Extracted from the article]

A recent study conducted at the University of Gondar in Ethiopia has found that pretreatment with lidocaine can significantly reduce the occurrence of postoperative myalgia caused by the muscle relaxant succinylcholine. The study involved 208 adult surgical patients and found that patients exposed to lidocaine had a lower incidence of myalgia compared to those who were not exposed. The study also identified other factors, such as the use of multimodal analgesia and non-steroidal anti-inflammatory drugs, as well as postoperative immobility and being male, that can help reduce succinylcholine-induced myalgia. This research provides valuable insights into preventive mechanisms for postoperative myalgia and highlights potential strategies for managing this condition. [Extracted from the article]

A retrospective study conducted by researchers at Shanxi Medical University in China compared the efficacy and adverse effects of oral ferrous succinate tablets and intravenous iron sucrose for the treatment of iron deficiency anemia. The study included 374 patients and found that both treatment groups showed improvements in hemoglobin, serum iron, serum ferritin, and mean corpuscular volume after four weeks of treatment. However, the group receiving intravenous iron sucrose had higher levels of these markers compared to the group receiving oral ferrous succinate tablets. The study concluded that iron sucrose is an effective and safe treatment for iron deficiency anemia. [Extracted from the article]

Researchers from South China Agricultural University have conducted a study on the immunomodulatory activity of Caulerpa chemnitzia polysaccharides (CRVP) in macrophages. The study found that CRVP promotes cell proliferation, upregulates cytokine expression, and increases levels of nitric oxide and reactive oxygen species. The researchers also discovered that succinic acid plays a key role in the immunomodulatory effects of CRVP by regulating the expression of prolyl hydroxylase domain 2 (PHD2) and hypoxia-inducible factor-1 alpha (HIF1 alpha), thereby enhancing IL-1(3 expression. The study concludes that CRVP exerts its immunomodulatory activity in macrophages through the succinate/PHD2/HIF-1 alpha/IL-1(3 pathway. [Extracted from the article]

A recent study conducted at NewYork-Presbyterian Brooklyn Methodist Hospital compared the success rates of two neuromuscular blocking agents, rocuronium and succinylcholine, for rapid sequence intubation in the emergency department. Previous studies had suggested that rocuronium had lower success rates compared to succinylcholine. However, this retrospective study found no significant difference in first-attempt intubation success between the two agents. The study suggests that further research is needed to evaluate the impact of weight-based dosing on intubation success. [Extracted from the article]

A patent application has been submitted for the approval of formulations of apremilast, a phosphodiesterase subtype IV (PDE4) inhibitor used to treat inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's Disease. The application describes oral dosage forms of apremilast that provide clinically desirable drug exposure. The dosage forms consist of a core tablet with a drug layer containing apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion, a swellable layer with one or more swellable polymers, and a coating layer with drug release orifices. The patent application provides various formulations and methods for administering the dosage forms. [Extracted from the article]

A recent study conducted by researchers at Albany Medical College in New York has found that reduced skeletal muscle mass and oxidative capacity are common in patients with pulmonary emphysema, and are associated with higher mortality rates. The study focused on the role of succinate dehydrogenase (SDH) in muscle dysfunction and found that reduced activity of SDH is a characteristic feature of muscle changes in pulmonary emphysema. However, the study also concluded that while SDH regulates myofiber respiration in experimental pulmonary emphysema, it does not control muscle mass or other body constituents. This research provides new insights into the relationship between pulmonary emphysema and muscle function. [Extracted from the article]

A patent application titled "Pharmaceutical Compositions Of An Epidermal Growth Factor Receptor Inhibitor" has been published online. The inventors have developed pharmaceutical compositions containing an intragranular phase and an extragranular phase. The intragranular phase consists of an amorphous solid dispersion of Compound (I) or a pharmaceutically acceptable salt, a pharmaceutically acceptable polymer, and a surfactant. The extragranular phase includes a surfactant, a disintegrant, a glidant, a lubricant, and a filler. The patent application provides detailed information about the composition and preparation methods. [Extracted from the article]

Researchers at Universitat Jaume I have reported new findings on anhydrides in a study titled "Performance Enhancement of Biopolyester Blends by Reactive Compatibilization with Maleic Anhydride-Grafted Poly(butylene succinate- co -adipate)." The study explores the use of poly(butylene succinate- co -adipate) grafted with maleic anhydride as a reactive additive to improve the performance of biopolyester blends used in food packaging. The researchers found that the compatibilized blends showed enhanced thermal stability, ductility, toughness, and improved barrier properties against water, limonene vapors, and oxygen. These findings suggest that the use of maleic anhydride-grafted biopolyesters can be an effective strategy to improve the properties of biopolyester blends for food packaging applications. [Extracted from the article]

A recent study conducted at Cairo University in Egypt has developed a new method for quantifying the antidepressant desvenlafaxine succinate (ODV) using a glassy carbon electrode (GCE) and multi-walled carbon nanotubes (MWCNTs). The electrode demonstrated a wide range of linearity and a low detection limit, making it an effective tool for quantifying ODV in various forms, including pure form, dosage form, and biological fluids such as urine and plasma. The researchers found that the method is environmentally friendly and cost-effective, making it suitable for use in quality control units, production units, hospitals, and clinical laboratories. The study has been peer-reviewed and published in the Microchemical Journal. [Extracted from the article]

Researchers from the Polytechnic University of Valencia in Spain have conducted a study on the valorization of rice straw into cellulose fibers for use in food packaging. They explored two green extraction methods, subcritical water extraction (SWE) and combined ultrasound-heating treatment (USHT), to obtain the fibers. The fibers were then pretreated with (3-glycidyloxypropyl) trimethoxysilane (GPS) and incorporated into poly(butylene succinate) (PBS) by melt-mixing. The resulting green composites were shaped into films by thermo-compression and showed improved rigidity and enhanced oxygen barrier properties, making them suitable for food packaging applications. [Extracted from the article]

A recent study conducted by researchers at Jamia Hamdard in New Delhi, India, has developed a new approach to targeting HIV-1 viral reservoirs using a combination of drugs. The researchers formulated a nanostructured lipid carrier decorated with D-alpha-tocopheryl polyethylene glycol succinate (TPGS) and loaded it with Etravirine (ETR) and Darunavir Ethanolate (DRVE). In vitro studies showed that this formulation was effective in inhibiting HIV-1 infection. The optimized lipid nanosystem also demonstrated improved drug release and enhanced oral bioavailability. These findings have the potential to reduce the side effects of high doses of antiretroviral drugs. [Extracted from the article]

The article offers information on the use of blood biomarkers for identifying carriers of succinate dehydrogenase gene variants. Topics discussed include the potential of these biomarkers for early tumor detection; the diagnostic performance of various metabolic ratios; and the effectiveness of plasma and erythrocyte biomarkers in distinguishing between individuals with and without genetic variants.

A patent application titled "Salts And Polymorphs Of Mitragynine And 3-Deuteromitragynine" has been published by the US Patent and Trademark Office. The application, filed by Andrew Kruegel and assigned to Kures Inc., discusses the need for alternative salts and crystalline forms of mitragynine and 3-deuteromitragynine, compounds derived from the Southeast Asian plant Mitragyna speciosa. These compounds have potential therapeutic properties for pain treatment and opioid addiction. The application provides details of various salts and their characteristics, as well as pharmaceutical compositions and methods of treatment using these salts. This information may be valuable for researchers exploring the potential therapeutic uses of these compounds in treating pain, mood disorders, anxiety disorders, substance use disorders, and withdrawal symptoms. [Extracted from the article]

A recent report from the Federal University Bahia in Salvador, Brazil discusses the therapeutic potential of Cannabidiol (CBD) in treating cancer. The study focuses on the development of CBD-loaded nanoparticles to enhance the drug's efficacy. The nanoparticles demonstrated anticancer effects in vitro, selectively reducing the viability of cancer cells without affecting non-transformed fibroblasts. The study suggests that this CBD nanoformulation has promising therapeutic potential and calls for further in vivo investigations. [Extracted from the article]

A recent report discusses research conducted at the Federal University Bahia in Salvador, Brazil, on the therapeutic properties of cannabidiol (CBD), a major component of Cannabis sativa. The study aimed to develop CBD-loaded nanoparticles and evaluate their effectiveness in cancer models. The nanoparticles demonstrated anticancer effects, selectively reducing the viability of cancer cells without affecting non-transformed fibroblasts. The study suggests that this CBD nanoformulation has therapeutic potential and warrants further investigation in vivo. [Extracted from the article]

This document is a patent application for a solid dispersion of a HER2 inhibitor, which is a potential treatment for oncological and hyperproliferative diseases, including various types of cancer. The solid dispersion consists of a compound that is amorphous and is present in a specific weight ratio with a pharmaceutically acceptable dispersion carrier. The patent application also describes a pharmaceutical composition that includes the solid dispersion and other excipients such as fillers, disintegrants, glidants, lubricants, and coating agents. The composition can be in the form of a tablet, granules, or a capsule. The patent application further includes a method for administering the solid dispersion to treat or prevent cancer, as well as a process for preparing the solid dispersion. A kit containing the solid dispersion and a container is also mentioned. [Extracted from the article]

A recent report from Okayama University in Japan discusses new research on chemicals and chemistry related to bone research. The study focuses on the synthesis and structural characterization of Sr2+-containing octacalcium phosphate (OCP) samples incorporated with 2,6-pyridinedicarboxylate (PA) ions and succinate (SA) ions. The researchers found that the SrOCPC sample at a PA/(PA+SA) molar ratio of 0.01 has the potential to be a novel bone defect filler with multiple drug loading capability. This research was funded by Grants-in-Aid for Scientific Research (KAKENHI), Okayama Foundation for Science and Technology, and Iketani Science and Technology Foundation. [Extracted from the article]

Researchers at the Institute for Pharmaceutical Sciences in Andhra Pradesh, India, have developed a new formulation of Valsartan, an angiotensin II inhibitor used in cardiovascular therapy. The study aimed to enhance the dissolution rate of Valsartan by forming complexes with beta-Cyclodextrin. The researchers successfully formulated fast-dissolving tablets of Valsartan using primojel and starch succinate as a novel super disintegrant. The optimized tablet demonstrated a disintegration time of only 15 seconds and an impressive 85.69% dissolution within 10 minutes. This research has been peer-reviewed and provides valuable insights into the development of Valsartan tablets. [Extracted from the article]

A recent study conducted by the Laboratory of Animal Health has found that a protein derived from Trichinella spiralis, a parasite, shows potential as a therapeutic molecule for allergic asthma. The protein, called Succinate Coenzyme A ligase beta-like protein (SUCLA-b), was found to have anti-inflammatory properties and was effective in reducing airway inflammation in a mouse model of asthma. The researchers concluded that the protein may inhibit allergic airway inflammation by regulating the immune response. This research provides new insights into potential treatments for allergic asthma. [Extracted from the article]

A recent study conducted by researchers at Central South University has found that succinate, an intermediate product of the TCA cycle, may have diagnostic and prognostic value in idiopathic pulmonary fibrosis (IPF). The study discovered that serum succinate levels were significantly higher in IPF patients compared to healthy controls, and a high level of succinate was associated with higher rates of disease progression and mortality. The researchers also found that succinate accumulation promotes fibroblast activation through the succinate receptor GPR91, leading to pulmonary fibrosis. These findings suggest that succinate could be a promising biomarker for the diagnosis and prognosis of IPF. [Extracted from the article]

A patent application has been filed for an amorphous form of pretomanid, a nitroimidazole anti-bacterial agent used in the treatment of tuberculosis (TB). Pretomanid has shown promising characteristics as a TB therapy, including activity against drug-resistant strains and a lack of mutagenicity. The invention aims to improve the solubility of pretomanid, potentially enhancing its effectiveness as a treatment. The patent application includes details of the amorphous form of pretomanid, pharmaceutical compositions, and methods of treatment. [Extracted from the article]

A recent study conducted at Brigham and Women's Hospital in Boston, Massachusetts, explored the role of miR-369-3p in diabetes-associated atherosclerosis. The researchers found that miR-369-3p expression was significantly lower in aortic intimal lesions from mice on a high-fat sucrose-containing diet and in peripheral blood mononuclear cells from diabetic patients with coronary artery disease. In vitro experiments showed that miR-369-3p overexpression reduced inflammation and metabolic alterations in macrophages. Therapeutic administration of miR-369-3p mimics in mice reduced atherosclerosis and increased macrophage efferocytosis in lesions. These findings suggest that miR-369-3p may have therapeutic potential in halting diabetes-associated atherosclerosis by regulating macrophage succinate metabolism. [Extracted from the article]

A recent study conducted at Ashikaga Red Cross Hospital has reported a case of potentially lethal malignant hyperthermia following electroconvulsive therapy (ECT) in a 79-year-old woman. Malignant hyperthermia is a life-threatening condition triggered by certain anesthetic drugs, particularly succinylcholine. This case highlights the delayed onset of malignant hyperthermia after ECT and emphasizes the importance of psychiatrists recognizing its symptoms and promptly treating it with dantrolene. The study underscores the need for close monitoring of patients' vital signs during and after ECT to prevent potentially lethal consequences. [Extracted from the article]

A research study conducted by Hunan University of Chinese Medicine explores the role of succinate in inflammation. Succinate, previously considered a byproduct of the tricarboxylic acid cycle, has been found to play a crucial role in inflammation. Excess succinate in the cytosol stabilizes hypoxia-inducible factor-1a, leading to enhanced inflammatory responses. Succinate also acts as a signaling molecule, modulating immune cell activities. The study suggests that targeting succinate pathways could offer potential therapeutic avenues for inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, obesity, and atherosclerosis. [Extracted from the article]

A report from Central Washington University discusses research on the synthesis of allylic 2-oxopyrrolidines, which are important components of certain pharmaceuticals. The researchers describe a flexible annulation strategy that combines succinic anhydride and 1,3-azadienes to produce these compounds. The approach is chemoselective, efficient, modular, scalable, and diastereoselective, allowing for post-diversification and the incorporation of motifs with pharmaceutical value. The research concludes that this strategy is a flexible and effective method for producing allylic 2-pyrrolidinones with contiguous stereocenters. [Extracted from the article]

Researchers at Kasetsart University in Bangkok, Thailand have developed sustainable poly(butylene succinate) (PBS) films with lignin nanoparticles (LN) and trans-cinnamaldehyde (CN) to preserve mango freshness and enhance food safety. The composite films demonstrated superior antifungal properties, inhibiting the growth of Colletotrichum gloeosporioides and extending the shelf life of mangoes. The study suggests that incorporating LN into PBS films can prolong the release of antifungal agents, reducing food waste and enhancing food safety. This research has been peer-reviewed and published in the International Journal of Biological Macromolecules. [Extracted from the article]

A patent application by Bayer Healthcare LLC has been made available online for a high concentration suspension formulation for cold and flu soft gel capsule medications. The invention aims to provide smaller dosage forms of these medications, which are more convenient and pleasant for consumers to take. The soft gel capsules contain a suspension with specific amounts of acetaminophen, dextromethorphan HBr, phenylephrine HCl, and optional additional active pharmaceutical ingredients. The method for preparing the soft gel capsules involves combining various ingredients and encapsulating the suspension with an outer shell mixture. [Extracted from the article]

A recent report from the University Clinical Center of Serbia discusses the findings of a study on leiomyomas, a type of tumor. The study focuses on two cases of uterine leiomyomas that exhibit rare histomorphological and genetic characteristics. These characteristics are important for prognosis and further treatment. The study emphasizes the need for careful examination and follow-up due to the predictive significance of these features, which can indicate additional hereditary cancer syndromes. [Extracted from the article]

A recent study conducted by the Korea Food Research Institute examined the effects of esterification with octenyl succinic anhydride (OSA) on the structural characteristics and glucose response of wheat starch. The researchers found that the treatment of wheat starch with OSA resulted in an increase in ester bonds, leading to an increase in the content of resistant starch (RS). Additionally, blood glucose levels and response in mice decreased as the concentration of OSA increased. The study suggests that OSA-modified starch could be used to produce functional foods for individuals with diabetes. [Extracted from the article]

A recent study conducted at Brigham and Women's Hospital in Boston, Massachusetts, has found that a specific microRNA, miR-369-3p, may have therapeutic potential in treating diabetes-associated atherosclerosis. The researchers discovered that miR-369-3p expression was significantly lower in aortic intimal lesions from mice on a high-fat sucrose diet and in peripheral blood mononuclear cells from diabetic patients with coronary artery disease. In vitro experiments showed that miR-369-3p overexpression reduced inflammation and metabolic alterations in macrophages. Therapeutic administration of miR-369-3p mimics in mice reduced atherosclerosis and inflammation. The study suggests that miR-369-3p may regulate macrophage succinate metabolism and could be a potential target for treating diabetes-associated atherosclerosis. [Extracted from the article]

A study conducted by researchers at the South China University of Technology explores the enzymatic synthesis of vitamin E succinate, a potential therapeutic agent for cancer treatment. The study focuses on the challenges associated with optimizing and scaling up the production of vitamin E succinate using lipases, particularly their poor stability in organic solvents. The researchers compare Lipase UM1 with three other immobilized commercial lipases and find that Lipase UM1 demonstrates enhanced resistance to organic solvents and superior efficiency in vitamin E succinate production. The study concludes that Lipase UM1 is a promising catalyst for industrial production of vitamin E succinate, with potential applications in cancer therapy. [Extracted from the article]

Amgen Inc. has been issued a patent for formulations of apremilast, a drug used to treat various inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's Disease. The patent describes oral dosage forms of apremilast that provide clinically desirable drug exposure. These dosage forms consist of a core tablet with a drug layer containing apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion, a swellable layer with one or more swellable polymers, and a coating layer with at least one drug release orifice. The patent provides specific details about the composition and ratios of the ingredients in the dosage forms. [Extracted from the article]

A recent study conducted at the University of Madras in Chennai, India, has yielded new findings on optoelectronics and nanotechnology. The researchers successfully synthesized and grew an organic nonlinear optical single crystal called 4-Hydroxypyridinium Succinate using the slow evaporation method. The crystal was found to have an orthorhombic structure and high transparency in the UV visible region. It also exhibited violet emission properties and belonged to the soft material category with reasonable hardness parameters. The crystal showed thermally stability up to 188°C and had a laser-induced damage threshold of 21.93 Gw/cm2. The study concluded that the crystal demonstrated second harmonic generation efficiency. [Extracted from the article]

A patent has been issued for a stable liquid formulation of AMG 416 (etelcalcetide), a peptide agonist of the calcium sensing receptor. The formulation has a pH of 2.0 to 5.0 and contains etelcalcetide at a concentration of 0.5 mg/mL to 15 mg/mL. The pH is maintained by a pharmaceutically acceptable buffer, such as succinate buffer, and the formulation may also include a tonicity modifier like sodium chloride. This liquid formulation is intended for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients and can be administered intravenously. The patent was filed by Amgen Inc. and published online on April 16, 2024. [Extracted from the article]

Crinetics Pharmaceuticals Inc. has been granted a patent for formulations of a somatostatin modulator, a hormone that regulates the endocrine system. The patent describes a spray-dried solid dispersion that includes a specific compound and a polymer. The compound-to-polymer ratio can vary, and the dispersion can contain at least 5% of the compound. The patent also details a method of suppressing certain hormones in humans using a pharmaceutical composition, which involves orally administering the composition on an empty stomach before a meal. For more information, consult the patent filed by Hannah Bulovsky of Crinetics Pharmaceuticals Inc. [Extracted from the article]

A recent study conducted by the Cardiovascular Diseases Research Group in Barcelona, Spain, explored the long-term effects of succinate dehydrogenase inhibition during reperfusion with malonate on post-infarction left ventricular scar and remodeling in mice. The researchers found that a single dose of malonate administered during the first 15 minutes of reperfusion resulted in a significant reduction in scar size and improved ejection fraction 28 days after infarction. This effect was associated with a decrease in the expression of pro-inflammatory and fibrotic markers in the myocardium. The findings suggest that succinate dehydrogenase inhibition with malonate may have long-term protective effects in mice subjected to transient coronary occlusion. [Extracted from the article]

A patent application titled "Diagnosis And Treatment Of Autism Spectrum Disorders Using Altered Ratios Of Metabolic Concentrations" is currently being reviewed by the US Patent and Trademark Office. The inventors propose a method for diagnosing and treating autism spectrum disorders (ASD) by analyzing metabolic pathways. The goal is to identify specific metabolic defects associated with ASD, enabling early detection and personalized interventions. The method involves measuring concentrations of metabolites and analyzing their ratios to identify imbalances and specific metabolic pathways. The patent application provides a comprehensive list of metabolites and their corresponding ratios that can be used in the analysis. [Extracted from the article]

A recent study conducted at Tianjin Medical University General Hospital in China has provided new insights into glioblastomas, a type of cancer. The research focused on the role of hypoxia, or oxygen deprivation, in glioblastoma development and the post-translational modification of oncogenic proteins. The study found that the HIF1 alpha and ATF3 proteins regulate the transcription of P4HA1, leading to increased succinate production and activation of HIF1 alpha signaling. This pathway may serve as a potential target for treating glioblastomas. The study was peer-reviewed and published in the journal Neuro-Oncology. [Extracted from the article]

Researchers at Punjabi University Patiala in Punjab, India have conducted a study on the use of polyelectrolyte complexes (PECs) for colon-specific release in the management of inflammatory bowel disease (IBD). The PECs, formed by the interaction between oppositely charged polymers, were found to have excellent stability and high encapsulation efficiency for both probiotics and prebiotics. In vitro studies showed enhanced survivability and proliferation of encapsulated probiotics in the presence of prebiotics. The treatment with synbiotic PECs in rats with induced colitis significantly relieved colitis symptoms. The study highlights the potential of PECs as a promising system for colon-specific synbiotic delivery, with implications for improved gut health and the treatment of various gastrointestinal disorders. [Extracted from the article]

A recent report from researchers at the National Institute of Pharmaceutical Education and Research in Telangana, India, discusses the development of raloxifene loaded nanoparticles for the treatment of breast cancer. Raloxifene is a selective estrogen receptor modulator that has shown promise in treating uterine and breast cancer. However, it has limitations in terms of low water solubility, extensive gut metabolism, and poor oral bioavailability. The researchers developed nanoparticles to offer sustained release through a parenteral route of administration. The nanoparticles demonstrated successful internalization in breast cancer cells and showed anti-proliferative activity. Further investigation is needed to determine the clinical viability of this approach. [Extracted from the article]

A study conducted by researchers at the University of Novi Sad in Serbia focused on the electrochemical behavior of solifenacin succinate (SOL), a drug commonly used for the treatment of urinary incontinence and urinary frequency. The study aimed to develop reliable and effective electrochemical sensors for SOL. The researchers tested three different working electrodes (gold, glassy carbon, and boron-doped diamond) and found that the SOL oxidation process is irreversible and diffusion-controlled. They also developed a differential pulse voltammetric (DPV) method for the electroanalytical determination of SOL, which showed excellent recovery and reproducibility. The study concluded that the boron-doped diamond electrode with the optimized DPV method could be used for trace-level electroanalytical determination of SOL in human urine samples. [Extracted from the article]

According to a preprint abstract, researchers have found that succinate, a compound found in the airway surface liquid (ASL) during infections, activates a receptor called SUCNR1, which in turn stimulates anion secretion, mucus transport, and bronchoconstriction in mouse airways. This activation pathway is linked to the function of the cystic fibrosis transmembrane conductance regulator (CFTR) channel, which is impaired in individuals with cystic fibrosis (CF). The researchers propose that succinate acts as a danger molecule that alerts the airways to the presence of pathogens, leading to a flushing out of the airways. However, this research has not yet undergone peer review. [Extracted from the article]

Researchers from Wuhan Polytechnic University have conducted a study on the treatment of neuroinflammation-based brain diseases. They developed multifunctional nanoparticles using octenyl succinic anhydride (OSA)-modified starch to carry selenium (Se) and folic acid (FA). These nanoparticles, called FA-OSAS-SeNPs, were found to ameliorate spatial learning and memory impairment caused by lipopolysaccharide (LPS)-induced inflammation. They also suppressed glial cell activation and the release of inflammatory factors, alleviated endoplasmic reticulum (ER) stress, and inhibited the overactivation of signaling pathways associated with inflammation. The researchers concluded that FA-OSAS-SeNPs show promise as an alternative or supplementary treatment for inflammatory brain diseases. [Extracted from the article]

A study conducted by researchers at Jagiellonian University in Krakow, Poland, explores the potential use of Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes. Mexidol, a synthetic derivative of vitamin B6, has been used by Russian athletes in the past and exhibits similar effects to drugs on the World Anti-Doping Agency (WADA) Prohibited List. The study suggests that combinations of these substances with succinate can enhance athletic performance. However, the researchers note that the line between performance enhancement and therapeutic drugs is becoming increasingly blurred, making it difficult to determine when a substance becomes a doping agent. [Extracted from the article]

A study conducted at Bharathidasan University in Kumbakonam, India, focused on the synthesis and analysis of a new organic crystal called 4-methylbenzylammonium hydrogen succinate (4MLBAHS). The researchers determined the crystal's structure and identified its space group. They also conducted various analyses, including vibrational analysis, UV-Vis-NIR analysis, and nuclear magnetic resonance spectroscopy, to understand the crystal's properties. The study found that the crystal exhibited third-order nonlinear optical characteristics, which were enhanced by the presence of hydrogen bond interactions. The research was supported by the Instrumentation Centre of St. Joseph's College and has been peer-reviewed. [Extracted from the article]